Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
Latest News
Call to make Opdivo+Yervoy first-line in melanoma
Treatment Trends: Australian study results to be presented to ASCO in the US next week show why immunotherapy should be first-line treatment for melanoma patients.
Industry convenes Christmas in July for homeless youth
Social Responsibility: The eighth annual Australian Healthcare Communicators for the Wayside fundraiser will celebrate 'Christmas in July' with a number of firsts and the aim of raising $20,000 for homeless youth in Sydney's Kings Cross. Tickets available now.
Is the dinner meeting dead?
Med Ed: Maybe not but it pays to beware of the 'knife and fork brigade' and widen your options, a marketing seminar has heard.
Diagnosis more use than drugs in beating cancer
Pipeline: Despite a stack of new drugs in the cancer pipeline, early diagnosis remains the key step to improving survival says Cancer Council CEO, Sanchia Aranda.
TGA drug fees up, but devices cut
Regulatory: Fees for most TGA cost-recovery activities will increase in July but those applying to some medical devices are being cut.
Govt backs clinical trials with $26m
Trials: A $26 million government investment in clinical trial capacity will allow Australians to access some of the latest breakthroughs in medical research, says Health Minister Hunt.
Most Popular
Your pharmacist is a 'govt agent'
Retail: As Health Minister Greg Hunt considers the King pharmacy review, review chair Professor Stephen King says pharmacists are best seen as 'agents of government'.
Novartis works on compliance after string of scandals
Compliance: Accusations and charges of bribery in South Korea, Greece, China and Turkey that have led to fines of close to US$75m have Novartis' signalling a new approach to compliance.
Hidden advantage for generics in bigger PBS cuts
Budget 2017-18: Bigger statutory price cuts announced in the budget increase the financial risk for pharmacos in defending patents, meaning generic drugs could come to market more quickly, say lawyers.
MA agreement may clash with PBAC mandate
Budget 2017/18: A legal analysis of last week's budget has concluded that elements of the industry/government agreement covering biosimilars and the PBAC may conflict with the committee's statutory mandate
Aussie pharmas move to block WannaCry
Cyber Threats: Australian pharmaceutical companies were yesterday implementing strategies to protect themselves after a global ransomware scare.
Trust survey delivers shock result for Aussie pharma
Reputation: In marked contrast to other parts of the world, public trust in pharma in Australia has fallen sharply says a new global survey.
Viagra ads could be on the way
Scheduling: Pfizer is seeking OTC status for Viagra with DTC advertising permission while Bayer has returned to the TGA with a second application for OTC Levitra.
Aspen investigated for price-gouging
Pricing: South African generic could face estimated fines of up to US$284 million as the EC launches its first anti-trust investigation for 'price- gouging' on five cancer medicines.
China biomed partnership bolsters Vic jobs
Innovation: An agreement between two Melbourne and Shanghai biomedical hubs is expected to create more jobs in Victoria.
Teva tops list of biggest generics
Companies: Despite a troubled year, Teva has topped Fierce Pharma's biggest generics of 2016 list, regaining the number one spot it held in 2014.
New Boehringer study adds millions to Pharmaxis payday
Innovation: Local drug developer Pharmaxis says BI is extending clinical development plans for its candidate PXS-4728A boosting milestone payments by tens of millions.
Approvals Action
New hope for metabolic disease
Alexion's orphan therapy Kanuma has been approved by the TGA for metabolic disease lysomal acid lipase deficiency.
Pipeline Monitor
Pfizer sets Xeljanz for psoriatic arthritis
Pfizer has filed Janus kinase inhibitor Xeljanz with the FDA in the hopes of a second indication in psoriatic arthritis for the star drug.
Debating Point
PBAC reform could be best of new agreement
The wider effects of the new agreement between the government and Medicines Australia will not be seen until proposed PBAC reforms become a reality.
FREE Content
Events & Conferences
Pharma in Focus Jobs